Repression of estrogen receptor β function by putative tumor suppressor DBC1

Biochemical and Biophysical Research Communications

Volumn 392, Issue 3, 2010, Pages 357-362

  Koyama, Satoshi ^a   Wada Hiraike, Osamu ^a   Nakagawa, Shunsuke ^a   Tanikawa, Michihiro ^a   Hiraike, Haruko ^a   Miyamoto, Yuichiro ^a   Sone, Kenbun ^a   Oda, Katsutoshi ^a   Fukuhara, Hiroshi ^a   Nakagawa, Keiichi ^a   Kato, Shigeaki ^b,c   Yano, Tetsu ^a   Taketani, Yuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

Breast cancer; DBC1; ER ; Repression; Transcription

Indexed keywords

DELETED IN BREAST CANCER 1 PROTEIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; GENE PRODUCT; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE REPRESSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; IMMUNOPRECIPITATION; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RNA INTERFERENCE; TRANSACTIVATION; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

BREAST NEOPLASMS; ESTROGEN RECEPTOR BETA; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; TRANSCRIPTION, GENETIC; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEINS;

EID: 76349118982     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.01.025     Document Type: Article

References (29)

1. Mangelsdorf D.J., Thummel C., Beato M., Herrlich P., Schutz G., Umesono K., Blumberg B., Kastner P., Mark M., Chambon P., and Evans R.M. The nuclear receptor superfamily: the second decade. Cell 83 (1995) 835-839
2. Metzger D., Ali S., Bornert J.M., and Chambon P. Characterization of the amino-terminal transcriptional activation function of the human estrogen receptor in animal and yeast cells. J. Biol. Chem. 270 (1995) 9535-9542
3. Lopez G.N., Webb P., Shinsako J.H., Baxter J.D., Greene G.L., and Kushner P.J. Titration by estrogen receptor activation function-2 of targets that are downstream from coactivators. Mol. Endocrinol. 13 (1999) 897-909
4. Lonard D.M., and O'Malley B.W. The expanding cosmos of nuclear receptor coactivators. Cell 125 (2006) 411-414
5. Wada-Hiraike O., Hiraike H., Okinaga H., Imamov O., Barros R.P., Morani A., Omoto Y., Warner M., and Gustafsson J.A. Role of estrogen receptor beta in uterine stroma and epithelium: insights from estrogen receptor beta-/- mice. Proc. Natl. Acad. Sci. USA 103 (2006) 18350-18355
6. Imamov O., Morani A., Shim G.J., Omoto Y., Thulin-Andersson C., Warner M., and Gustafsson J.A. Estrogen receptor beta regulates epithelial cellular differentiation in the mouse ventral prostate. Proc. Natl. Acad. Sci. USA 101 (2004) 9375-9380
7. Wada-Hiraike O., Imamov O., Hiraike H., Hultenby K., Schwend T., Omoto Y., Warner M., and Gustafsson J.A. Role of estrogen receptor beta in colonic epithelium. Proc. Natl. Acad. Sci. USA 103 (2006) 2959-2964
8. Hamaguchi M., Meth J.L., von Klitzing C., Wei W., Esposito D., Rodgers L., Walsh T., Welcsh P., King M.C., and Wigler M.H. DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc. Natl. Acad. Sci. USA 99 (2002) 13647-13652
9. Sundararajan R., Chen G., Mukherjee C., and White E. Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene 24 (2005) 4908-4920
10. Kim J.E., Chen J., and Lou Z. DBC1 is a negative regulator of SIRT1. Nature 451 (2008) 583-586
11. Zhao W., Kruse J.P., Tang Y., Jung S.Y., Qin J., and Gu W. Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451 (2008) 587-590
12. Fu J., Jiang J., Li J., Wang S., Shi G., Feng Q., White E., Qin J., and Wong J. Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J. Biol. Chem. 284 (2009) 6832-6840
13. Zhang L.J., Liu X., Gafken P.R., Kioussi C., and Leid M. A chicken ovalbumin upstream promoter transcription factor I (COUP-TFI) complex represses expression of the gene encoding tumor necrosis factor alpha-induced protein 8 (TNFAIP8). J. Biol. Chem. 284 (2009) 6156-6168
14. Garapaty S., Xu C.F., Trojer P., Mahajan M.A., Neubert T.A., and Samuels H.H. Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J. Biol. Chem. 284 (2009) 7542-7552
15. Trauernicht A.M., Kim S.J., Kim N.H., and Boyer T.G. Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol. Endocrinol. 21 (2007) 1526-1536
16. Wada-Hiraike O., Yano T., Nei T., Matsumoto Y., Nagasaka K., Takizawa S., Oishi H., Arimoto T., Nakagawa S., Yasugi T., Kato S., and Taketani Y. The DNA mismatch repair gene hMSH2 is a potent coactivator of oestrogen receptor alpha. Br. J. Cancer 92 (2005) 2286-2291
17. Fujita T., Kobayashi Y., Wada O., Tateishi Y., Kitada L., Yamamoto Y., Takashima H., Murayama A., Yano T., Baba T., Kato S., Kawabe Y., and Yanagisawa J. Full activation of estrogen receptor alpha activation function-1 induces proliferation of breast cancer cells. J. Biol. Chem. 278 (2003) 26704-26714
18. Castro A., Johnson M.C., Anido M., Cortinez A., Gabler F., and Vega M. Role of nitric oxide and bcl-2 family genes in the regulation of human endometrial apoptosis. Fertil Steril 78 (2002) 587-595
19. Cha E.J., Noh S.J., Kwon K.S., Kim C.Y., Park B.H., Park H.S., Lee H., Chung M.J., Kang M.J., Lee D.G., Moon W.S., and Jang K.Y. Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin. Cancer Res. 15 (2009) 4453-4459
20. Roger P., Sahla M.E., Makela S., Gustafsson J.A., Baldet P., and Rochefort H. Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res. 61 (2001) 2537-2541
21. Shaw J.A., Udokang K., Mosquera J.M., Chauhan H., Jones J.L., and Walker R.A. Oestrogen receptors alpha and beta differ in normal human breast and breast carcinomas. J. Pathol. 198 (2002) 450-457
22. Park B.W., Kim K.S., Heo M.K., Ko S.S., Hong S.W., Yang W.I., Kim J.H., Kim G.E., and Lee K.S. Expression of estrogen receptor-beta in normal mammary and tumor tissues: is it protective in breast carcinogenesis?. Breast Cancer Res. Treat. 80 (2003) 79-85
23. Omoto Y., Eguchi H., Yamamoto-Yamaguchi Y., and Hayashi S. Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22 (2003) 5011-5020
24. Tonetti D.A., Rubenstein R., DeLeon M., Zhao H., Pappas S.G., Bentrem D.J., Chen B., Constantinou A., and Craig Jordan V. Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells. J. Steroid Biochem. Mol. Biol. 87 (2003) 47-55
25. Kelloff G.J., Lippman S.M., Dannenberg A.J., Sigman C.C., Pearce H.L., Reid B.J., Szabo E., Jordan V.C., Spitz M.R., Mills G.B., Papadimitrakopoulou V.A., Lotan R., Aggarwal B.B., Bresalier R.S., Kim J., Arun B., Lu K.H., Thomas M.E., Rhodes H.E., Brewer M.A., Follen M., Shin D.M., Parnes H.L., Siegfried J.M., Evans A.A., Blot W.J., Chow W.H., Blount P.L., Maley C.C., Wang K.K., Lam S., Lee J.J., Dubinett S.M., Engstrom P.F., Meyskens Jr. F.L., O'Shaughnessy J., Hawk E.T., Levin B., Nelson W.G., and Hong W.K. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin. Cancer Res. 12 (2006) 3661-3697
26. Meyers M.J., Sun J., Carlson K.E., Marriner G.A., Katzenellenbogen B.S., and Katzenellenbogen J.A. Estrogen receptor-beta potency-selective ligands: structure-activity relationship studies of diarylpropionitriles and their acetylene and polar analogues. J. Med. Chem. 44 (2001) 4230-4251
27. Malamas M.S., Manas E.S., McDevitt R.E., Gunawan I., Xu Z.B., Collini M.D., Miller C.P., Dinh T., Henderson R.A., Keith Jr. J.C., and Harris H.A. Design and synthesis of aryl diphenolic azoles as potent and selective estrogen receptor-beta ligands. J. Med. Chem. 47 (2004) 5021-5040
28. Yamamoto Y., Shibata J., Yonekura K., Sato K., Hashimoto A., Aoyagi Y., Wierzba K., Yano S., Asao T., Buzdar A.U., and Terada T. TAS-108, a novel oral steroidal antiestrogenic agent, is a pure antagonist on estrogen receptor alpha and a partial agonist on estrogen receptor beta with low uterotrophic effect. Clin. Cancer Res. 11 (2005) 315-322
29. Blakely L.J., Buzdar A., Chang H.Y., Frye D., Theriault R., Valero V., Rivera E., Booser D., Kuritani J., and Tsuda M. A phase I and pharmacokinetic study of TAS-108 in postmenopausal female patients with locally advanced, locally recurrent inoperable, or progressive metastatic breast cancer. Clin. Cancer Res. 10 (2004) 5425-5431